Explain me b adrenergic blocker
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have rich content from Goodman & Gilman's. Let me compile a comprehensive answer.
Beta-Adrenergic Blockers (β-Blockers)
What Are They?
Beta-adrenergic blockers are competitive antagonists of β-adrenergic receptors. They block the effects of catecholamines (adrenaline, noradrenaline) at beta receptors, reducing sympathetic nervous system activity. They have received enormous clinical attention due to efficacy in hypertension, ischemic heart disease, heart failure, and arrhythmias.
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
Beta-Receptor Subtypes (What They Block)
| Receptor | Location | Stimulation Effect | Blockade Effect |
|---|---|---|---|
| β1 | Heart, juxtaglomerular cells | ↑ HR, ↑ contractility, ↑ renin | ↓ HR, ↓ contractility, ↓ renin |
| β2 | Bronchial smooth muscle, blood vessels, uterus | Bronchodilation, vasodilation | Bronchoconstriction (side effect) |
| β3 | Adipose tissue, bladder | Lipolysis, bladder relaxation | Minimal clinical relevance |
Classification of Beta-Blockers
Beta-blockers are classified into three generations based on their properties:
Generation 1 - Non-Selective (block both β1 and β2)
- Propranolol - the prototype; equal β1 and β2 affinity
- Nadolol - also non-selective
- Timolol - used in glaucoma
- Sotalol - also has Class III antiarrhythmic activity
Generation 2 - Cardioselective / β1-Selective
Preferentially block β1 receptors, less risk of bronchoconstriction:
- Metoprolol (succinate or tartrate)
- Atenolol
- Bisoprolol
- Esmolol - ultra-short acting (IV), half-life ~9 minutes
- Acebutolol - also has intrinsic sympathomimetic activity (ISA)
Generation 3 - Vasodilatory Beta-Blockers
Block α1 receptors or produce vasodilation via other mechanisms in addition to β-blockade:
- Carvedilol - blocks α1 + β1 + β2; also has antioxidant properties
- Labetalol - blocks α1 + β1 + β2 (used in hypertensive emergencies in pregnancy)
- Nebivolol - β1-selective + stimulates NO release → vasodilation
Key Pharmacological Properties That Distinguish Them
1. Cardioselectivity (β1 Selectivity)
β1-selective agents (metoprolol, atenolol, bisoprolol) are preferred in:
- Asthma / COPD - less bronchoconstriction
- Diabetes - less masking of hypoglycemia symptoms
- Peripheral vascular disease
- Raynaud syndrome
Note: selectivity is not absolute - at high doses, β1-selective drugs also block β2 receptors.
2. Intrinsic Sympathomimetic Activity (ISA)
Some beta-blockers (pindolol, acebutolol) are partial agonists - they partially activate β receptors even while blocking them. This:
- Prevents profound bradycardia at rest
- May be preferred in patients with resting bradycardia
- However, may be disadvantageous for secondary MI prevention (less cardioprotection)
3. Membrane-Stabilizing Activity (MSA)
Local anesthetic-like effect, independent of β-blockade. Seen with propranolol, acebutolol, carvedilol. Clinically relevant mainly in overdose situations.
4. Lipid Solubility (CNS Penetration)
| Property | Drug | Clinical Impact |
|---|---|---|
| High lipophilicity | Propranolol, metoprolol, carvedilol | More CNS effects (depression, nightmares, fatigue) |
| Low lipophilicity | Atenolol, nadolol | Less CNS penetration; renally excreted |
Mechanism of Action
By blocking β-adrenergic receptors, these drugs:
- Heart - Decrease heart rate (negative chronotropy), decrease contractility (negative inotropy), decrease conduction velocity through AV node (negative dromotropy)
- Kidneys - Decrease renin secretion (β1 blockade on juxtaglomerular cells)
- Blood vessels - Initially peripheral resistance may increase (block of vasodilatory β2); long-term leads to decreased BP
- Lungs - Non-selective agents can cause bronchoconstriction (β2 blockade)
Clinical Indications
| Condition | Drug(s) of Choice | Mechanism |
|---|---|---|
| Hypertension | Metoprolol, atenolol, bisoprolol | ↓ CO + ↓ renin |
| Angina pectoris | Metoprolol, atenolol, propranolol | ↓ O2 demand (↓ HR, ↓ contractility) |
| Heart failure (systolic) | Carvedilol, metoprolol succinate, bisoprolol | ↓ sympathetic overdrive; improves LV remodeling |
| Post-MI (secondary prevention) | Metoprolol, propranolol | ↓ reinfarction, ↓ sudden death |
| Arrhythmias (SVT, AF rate control) | Metoprolol, esmolol (IV), propranolol | ↓ AV conduction |
| Hyperthyroidism (symptomatic) | Propranolol | Blocks adrenergic symptoms + inhibits T4 → T3 conversion |
| Migraine prophylaxis | Propranolol, timolol, metoprolol | Reduces sympathetic vascular changes |
| Glaucoma | Timolol (topical) | Decreases aqueous humor production |
| Anxiety / performance anxiety | Propranolol | Controls peripheral adrenergic symptoms (palpitations, tremor) |
| Portal hypertension (variceal bleed prevention) | Propranolol, nadolol | Reduces portal venous pressure |
| Phaeochromocytoma | ALWAYS give α-blocker FIRST, then β-blocker | Prevents unopposed α-stimulation hypertensive crisis |
Adverse Effects
| Side Effect | Mechanism | At-Risk Group |
|---|---|---|
| Bradycardia / heart block | Excessive β1 blockade | Patients with sinus node disease, AV block |
| Bronchoconstriction | β2 blockade | Asthmatics, COPD |
| Cold extremities | β2 blockade → peripheral vasoconstriction | Raynaud, PVD |
| Masking hypoglycemia | β2 blockade suppresses glycogenolysis; tachycardia warning blunted | Diabetics on insulin |
| CNS effects (fatigue, depression, nightmares) | Lipophilic agents penetrating CNS | More common with propranolol |
| Erectile dysfunction | Non-selective agents (propranolol) > others | Seen especially vs ACE inhibitors |
| Rebound hypertension/angina | Upregulation of β receptors after chronic blockade | Abrupt withdrawal - MUST taper |
Important Contraindications
- Absolute: Severe bradycardia, high-degree AV block (without pacemaker), decompensated acute heart failure, severe bronchospastic disease
- Relative: Diabetes (insulin-dependent), peripheral vascular disease, depression, Raynaud syndrome
Critical warning: In phaeochromocytoma, never give a beta-blocker without an alpha-blocker first - this causes unopposed alpha stimulation and can trigger a dangerous hypertensive crisis. - Rosen's Emergency Medicine
Pharmacokinetics Summary
| Drug | Route | Half-life | Selectivity | Special Feature |
|---|---|---|---|---|
| Propranolol | Oral/IV | 3-6 hr | Non-selective | Prototype; high first-pass metabolism (~75%); highly lipophilic |
| Metoprolol | Oral/IV | 3-7 hr | β1-selective | Available as tartrate (IR) and succinate (XL); used in HF |
| Atenolol | Oral | 6-9 hr | β1-selective | Renally excreted; low lipophilicity |
| Esmolol | IV only | ~9 min | β1-selective | Ultra-short acting; used in acute settings (AF, hypertensive urgency) |
| Carvedilol | Oral | 6-10 hr | Non-selective + α1 | Used in HF; antioxidant properties |
| Labetalol | Oral/IV | 3-8 hr | Non-selective + α1 | Preferred in hypertensive emergencies in pregnancy |
| Bisoprolol | Oral | 10-12 hr | β1-selective (most selective) | Used in HF (CIBIS-II trial) |
| Nebivolol | Oral | 12-19 hr | β1-selective | NO-mediated vasodilation; metabolic benefits |
Withdrawal
Never stop beta-blockers abruptly. Long-term use leads to upregulation (increased density) of β-adrenergic receptors. Abrupt withdrawal causes enhanced sensitivity to catecholamines, which can precipitate:
- Rebound hypertension
- Unstable angina or myocardial infarction
- Arrhythmias
Always taper gradually over 1-2 weeks.
Summary
Beta-blockers are a cornerstone of cardiovascular pharmacology. The key to using them wisely is understanding:
- Which receptor subtypes are blocked (selective vs. non-selective)
- Whether the drug has added properties (ISA, α-blockade, NO release)
- The pharmacokinetics (lipophilicity, route, half-life)
- Patient-specific contraindications (especially asthma and AV block)
Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics; Braunwald's Heart Disease; Fuster and Hurst's The Heart, 15th Edition; Katzung's Basic and Clinical Pharmacology, 16th Edition; Rosen's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.